Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts

Key Points

• Analysts give Keros Therapeutics a consensus "Hold" rating (1 sell, 4 hold, 4 buy) with an average 12‑month price target of $21.33, compared with a recent open near $11.49.
• KROS reported a quarterly earnings miss—EPS of -$0.86 vs. -$0.49 expected and revenue of $0.39M vs. $3.66M expected, a 87.2% year‑over‑year revenue decline; analysts project -$5.51 EPS for the year.
• Institutional investors own about 71.56% of the shares; the stock trades near its 12‑month low ($10.41) with a market cap around $227 million.

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have earned a consensus rating of "Hold" from the nine analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $21.3333.

KROS has been the subject of a number of research analyst reports. Wells Fargo & Company dropped their price target on Keros Therapeutics from $23.00 to $20.00 and set an "overweight" rating for the company in a research report on Thursday, March 5th. Wall Street Zen downgraded Keros Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 7th.

Keros Therapeutics Trading Up 3.3%

Shares of KROS opened at $11.49 on Friday. The company has a market cap of $227.39 million, a PE ratio of 6.31 and a beta of 0.95. The stock has a 50-day moving average price of $12.01 and a 200-day moving average price of $15.91. Keros Therapeutics has a 12-month low of $10.41 and a 12-month high of $22.55.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Wednesday, March 4th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.37). The business had revenue of $0.39 million for the quarter, compared to the consensus estimate of $3.66 million. Keros Therapeutics had a net margin of 35.65% and a return on equity of 14.25%. The business's revenue was down 87.2% compared to the same quarter last year. During the same quarter last year, the business posted ($1.14) EPS. As a group, analysts predict that Keros Therapeutics will post -5.51 earnings per share for the current year.

Institutional Trading of Keros Therapeutics

A number of large investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company boosted its position in shares of Keros Therapeutics by 8.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company's stock valued at $166,000 after acquiring an additional 988 shares during the last quarter. UBS Group AG raised its holdings in shares of Keros Therapeutics by 1.1% during the 3rd quarter. UBS Group AG now owns 103,864 shares of the company's stock valued at $1,643,000 after buying an additional 1,091 shares in the last quarter. Strs Ohio raised its holdings in shares of Keros Therapeutics by 3.9% during the 4th quarter. Strs Ohio now owns 29,300 shares of the company's stock valued at $597,000 after buying an additional 1,100 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in shares of Keros Therapeutics by 254.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company's stock valued at $33,000 after buying an additional 1,166 shares in the last quarter. Finally, Financial Management Professionals Inc. purchased a new position in shares of Keros Therapeutics during the 4th quarter valued at about $29,000. Institutional investors own 71.56% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc NASDAQ: KROS is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company's research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company's lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.